Trial Profile

A Phase I randomized double-blind, three-arm, single-dose study to compare pharmacokinetics, safety and tolerability of DMB-3115 with its reference products (US- and EU-marketed products under the name of Stelara®) in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary)
Indications Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
Focus Adverse reactions; Pharmacokinetics

20 May 2021 Results published in the Meiji Seika Pharma Media Release.
18 Dec 2019 New trial record
13 Dec 2019 According to a Meiji Seika Pharma and Dong-A Socio Holdings media release, the dosing of subjects in this trial is started

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com